New Drugs for Optic Nerve Disorders Coming Down the Pipeline, 2018 : Researchmoz

Researchmoz added Most up-to-date research on “Optic Nerve Disorders Drug Development Pipeline Review, 2018” to its huge collection of research reports.

This report provides an overview of the pipeline landscape for disorders of the optic nerve, the bundle of nerve fibers that transmits visual information from the eye to the brain. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for optic neuropathy, glaucoma, Lebers hereditary optic neuropathy (LHON) and optic neuritis, and features dormant and discontinued products.

FREE| Request Sample is Available at:

Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. There are 10 products in development for this indication.

Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. Signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision and reddening of the eye. There are 13 products in development for this indication.

LHON is an inherited form of vision loss. This condition usually begins in a persons teens or twenties. Males are affected much more often than females. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. There are 16 products in development for this indication.

Optic neuritis refers to inflammation of the optic nerve. Symptoms include pain, vision loss, dyschromatopsia (impaired ability to perceive colors) and flashing lights. There are 12 products in development for this indication.

Molecular targets acted on by products in development for optic nerve disorders include kinases, growth factors and cannabinoid receptors. Companies operating in this pipeline space include NicOx SA Regeneron Pharmaceuticals and Amgen.

View Complete TOC with tables & Figures @


– Which companies are the most active within each pipeline?
– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
– What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy

Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Make An Enquiry @

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: ;
Follow us on LinkedIn @
Follow us on Blogger at :

Click Here to Continue...

Add a Comment

Your email address will not be published. Required fields are marked *